Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

The mechanism of action of bempedoic acid

Feb. 2, 2020

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##SCROLLER_ITEMS_FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Increased atherogenicity of LDL and impaired HDL function in children with FH

News - June 7, 2021

EAS 2021 This study showed that children with familiar hypercholesterolemia had an increased susceptibility of LDL particles to form aggregates and a reduced cholesterol efflux capacity of HDL compared to healthy children.

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.

Genetic testing for autosomal dominant hypercholesterolemia in Norwegian patients and relatives

Literature - Apr. 20, 2021 - Leren TP and Bogsrud MP. - Atherosclerosis. 2021

Heterozygous LDLR gene mutations were most prevalent when screening for autosomal dominant hypercholesterolemia in hypercholesterolemia patients and relatives from Norway.

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.

FDA approves PCSK9 inhibitor for patients with HoFH

News - Apr. 6, 2021

The PCSK9 inhibitor alirocumab has been approved by the US Food and Drug Administration (FDA) as an adjunct to other LDL-c lowering therapies for the treatment of adult patients with homozygous familial hypercholesterolemia.

Elevated MI risk in patients with HeFH with gene variants in both LDLR and PCSK9

Literature - Mar. 16, 2021 - Doi T, et al. - J Am Heart Assoc. 2021

Patients with LDLR and PCSK9 gene variants had higher levels of LDL-c and more frequent occurrence of nonfatal MI than those with single LDLR variants. This was especially observed in men.

ANGPTL3 inhibitor approved by FDA for patients with HoFH

News - Feb. 15, 2021

The FDA approved the ANGPTL3 inhibitor evinacumab for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) to lower LDL-c.

Angiopoietin-like 3 antibody halves LDL-c levels in patients with refractory hypercholesterolemia

Literature - Jan. 18, 2021 - Rosenson RS, et al. - N Engl J Med. 2020

This phase 2 trial showed that ANGPTL3 inhibition by evinacumab significantly reduced LDL-c by ~50% at maximum dose in patients with refractory hypercholesterolemia.

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

Inclisiran has received approval from the European Commission (EC) for the treatment of adult patients with atherosclerotic CVD (ASCVD), ASCVD-risk equivalent and heterozygous FH.

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

Following the results from the ORION program, the CHMP of EMA has issued a positive opinion on inclisiran to reduce LDL-c in patients with hypercholesterolemia or mixed dyslipidemia.